

// 11 MAY 2021

## **eTheRNA immunotherapies conference attendance for May- June 2021**

### **Niel (Belgium)**

eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing LNP-formulated mRNA immunotherapies as off-the shelf products for the treatment of cancer and infectious diseases, will be attending the following conferences during May and June:

#### [BioEquity Europe](#)

17–19 May 2021

Steven Powell, CEO will be speaking as part of the 'West-East Roundtable: Next Act Europe-China Collaborations' panel, on Tuesday 18th May 2021.

- Volker Germaschewski, Senior VP of R&D, Michael Mulqueen, VP of Business Development, Ulrich Platte, CFO and Tim Van Assche, Director of Business Development & Alliance Management, will also be attending the conference.

#### [Sachs 7th Immuno-oncology Innovation Forum](#)

18–20 May 2021

Michael Mulqueen, VP of Business Development will be speaking as part of the 'Cancer Vaccines, Neo Antigens & Related Modalities' panel, on Wednesday 19th May 2021 at 8.50am CET.

#### [AngloNordic Conference](#)

25–26 May 2021

Steven Powell, CEO will be speaking on the 'If I knew then what I know now' panel, on Wednesday 26th May 2021 at 5.15pm CET.

#### [Flanders Vaccine General Assembly](#)

27 May 2021

Marina Cools, VP of Clinical Development will be speaking as part of the Flanders Vaccine General Assembly, on Thursday 27th May 2021.

#### [Informa Industry Experts Panel](#)

9 June 2021

Steven Powell, CEO will be speaking as part of the 'Designing the Deal' panel, on Wednesday 9th June 2021 at 1pm CET.

#### [Belfius and Kepler Cheuvreux Digital Life Science Days](#)

21-22 June 2021

Steven Powell, CEO will be giving a presentation on the Company, on Tuesday 22nd June 2021.

#### [About eTheRNA immunotherapies NV](#)

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its multiple RNA, formulation and manufacturing technology platforms. The company is headquartered in Belgium and was established in 2013. Its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA's R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.